RecruitingEarly Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Cervical Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Eligible age
18+ yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
Sponsor: Mayo Clinic
You may qualify if…
- ✓ Subjects must meet one of the following criteria:
- ✓ Subjects suspected of or diagnosed with the following Stage IV/metastatic or recurrent malignancies:
- ✓ Lung: Non-small Cell Lung Cancer (NSCLC)
- ✓ Skin: Cutaneous Malignancy, excluding Uveal Melanoma
- ✓ Esophageal Cancer
- ✓ Cervical Cancer
- ✓ Endometrial Cancer
- ✓ Colon Cancer: Mismatch repair deficient (dMMR) CRC only
You may not qualify if…
- ✕ Pregnant women because this study involves a greater than minimal risk procedure (biopsy)
- ✕ Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety for the biopsy
- ✕ Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy
- ✕ NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
- ✕ Uncontrolled intercurrent illness including, but not limited to:
- ✕ ongoing or active infection
- ✕ psychiatric illness/social situations that would limit compliance with study requirements
- ✕ Subjects who are enrolled or plan to be enrolled in a blinded cancer therapeutic treatment trial
Where it's recruiting
Source: ClinicalTrials.gov · NCT06349642 · last updated 2026-03-12